From May 5th to 7th, the 7th Future Medical Top 100 Conference sponsored by VB100, VBdate, and VCBeat Research was grandly held at the Zhangjiang Science Hall in Shanghai. The conference received strong support from the Shanghai Pudong District Government and Zhangjiang Group, and brought together many Chinese and foreign academicians and experts in various fields, including the internationally renowned scientist Professor Robert Langer .
Professor Robert Langer’s speech
As an expert with many years of experience in pharmaceutical technology transfer, Dr. Tom Du, chairman of Evergreen, hosted a roundtable forum with listed pharmaceutical company in the United States, innovative pharmaceutical companies in China, well-known investment institutions, and pharmaceutical experts from Wall Street, celebrities the first day of the Trend Summit entitled "Why is it difficult for China's innovative drugs to go overseas? Where is the road?" , discussed international technology transfer, especially international license-out and other hot topics of current concern. The experts commented on the current situation of the transfer of China's innovative pharmaceutical drugs and made suggestions.
Dr. Tom Du hosted the roundtable session
During the conference , the 2023 VB100 Future Medical Top 100 series list was also officially announced. With its strength and innovation capabilities in the field of AI drug development, Evergreen successfully ranked among the " TOP 100 China's Innovative Biopharmaceuticals " and became one of the only 5 One of the companies was awarded the "AI Pharmaceutical Value Field Award" .
Evergreen was named as "China's Top 100 Innovative Biotech"
Founded in 2015, the Future Medical Top 100 list is the first domestic innovative medical field list for unlisted companies launched by VB100, VBdate, and VCBeat Research. It aims to select China's innovative medical care companies that truly represent future medical care. Those who want to discover the core strength of my country's future medical industry and promote the innovation and transformation process of the health care industry. Evergreen has been selected into the Future Medical Top 100 of "China's Innovative Biotech TOP 100 " list for the second consecutive year after 2022 .
This selection is open to non-listed companies in the medical and health field. The selection is based on the VB100 value assessment model, through the process of independent application by enterprises, review by the VB100 review meeting, cross-review by supporting institutions, and final review by the expert committee, from five major fields (medical devices/biomedicine/digital health/medical services/business and supply chain Services) to select the top 100 innovative companies with valuation rankings. In addition to valuation, the candidate company will be supplemented by a supplementary examination of its growth and annual performance in terms of four primary indicators: human resources, knowledge resources, important partner resources, and market performance, and a total of 17 secondary indicator data.
Evergreen won the "AI Pharmaceutical Value Award"
It is worth noting that it won another "AI Pharmaceutical Value Award" this year. The award is conducted every year through investor interviews, reporter interviews, industry report reading and other multi-directional and all-round insights and explorations. It is based on capital attention, supplemented by media focus, annual medical and health enterprise performance data popularity, and the future medical and health industry development prosperity. Taking into consideration three aspects of development prosperity, we conducted an inventory of 60+ subdivided fields in the four major tracks of medical devices, biomedicine, digital medicine, and medical services, selected the most representative value fields of the year, and selected the most representative value fields in each value field. At the same time, the most representative and growing innovative enterprises in each value field are selected.
As an international innovative pharmaceutical company focusing on the development and application of biological and clinical AI platforms, Evergreen always adheres to differentiated innovation and promotes "Dual Business Model" operations. It applies its self-developed AI platform to conduct its own pipeline research and development and external service, have achieved rapid development. This time becoming one of only five companies to win this award in the "AI pharmaceuticals" subdivision is not only recognition of Evergreen's growth by all parties in the industry, but also an affirmation of the value brought by the high-value pipeline developed by the company and the new drug development services it provides.
